News

Trial immunosuppressive therapy benefits outweigh long-term lymphoma risks in IBD

Publish date: January 22, 2014

 

EXPERT ANALYSIS AT 2013 ADVANCES IN IBD

Dr. Lewis disclosed that he consults for AbbVie, Janssen, Prometheus, and Millennium and has received research funding from Centocor and Takeda.

wmcknight@frontlinemedcom.com

Pages

Recommended Reading

Methotrexate less risky for lungs in RA than previously thought
MDedge Internal Medicine
VIDEO: What's next for lung cancer detection and treatment?
MDedge Internal Medicine
Comfort care informs critical care societies’ Choosing Wisely list
MDedge Internal Medicine
Combo therapy for tobacco dependence
MDedge Internal Medicine
In the real world, persistence on warfarin is low
MDedge Internal Medicine
Statins reduce recurrent thromboembolism risk
MDedge Internal Medicine
Oseltamivir suspension back in production
MDedge Internal Medicine
Perception of safety spurs e-cigarette use in young adults
MDedge Internal Medicine
Surgeon General report links smoking to diseases beyond cancer
MDedge Internal Medicine
Imaging, biomarkers, clinical findings guide approach to indeterminate pulmonary nodules
MDedge Internal Medicine